Can Vepotolizumab/Urova cure cancer diseases?

Polatuzumab/Polatuzumab, as an antibody-drug conjugate (ADC), is an innovative targeted drug for CD79b-positive B-cell lymphoma. It combines precise immune recognition function with powerful cytotoxicity to directly deliver drugs into cancer cells and trigger cell apoptosis. This mechanism brings new hope to patients with refractory non-Hodgkin lymphoma, but whether a "radical cure" can be achieved still depends on the individual condition and disease stage.

Vepotolizumab is mainly used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). It is suitable for adult patients who have not improved or relapsed after at least two chemotherapy regimens. Combined use with Bendamustine and Rituximab can significantly improve the response rate and prolong survival time. Since DLBCL is a type of lymphoma that is highly aggressive and prone to relapse, traditional chemotherapy and monoclonal antibody treatment are often difficult to achieve complete cure. Therefore, velpotuzumab is positioned more as a targeted therapy that "delays disease progression and improves survival rate" rather than a radical cure in an absolute sense.

However, overseas studies have shown that some patients who are highly sensitive to treatment can achieve durable complete remission (CR) after receiving thePola-BR regimen, and no recurrence occurs in long-term follow-up. This situation suggests that velpotuzumab has the potential to be a "functional cure" in some patients, especially in patients with low disease burden and good immune function recovery. If used in combination with CAR-T therapy, radiotherapy or new immune drugs in the future, the radical cure potential of vepotuzumab may be further expanded.

Therefore, vepotuzumab can currently be regarded as a "deep remission" drug that can significantly improve prognosis and extend survival, but whether it can achieve long-term cure still requires more clinical data to support. For patients, scientific evaluation of efficacy, close monitoring of the condition, and combined treatment are the keys to maximizing its clinical value.

Reference materials:https://www.drugs.com/polivy.html